Endocrine Abstracts

Background: Primary hyperaldosteronism (PHA) is the most frequent type of endocrine hypertension with a prevalence that is continuously rising. Following the introduction of diagnostic tests that consider both the adrenocorticotropic hormone effect andrenin–angiotensin–aldosterone system (RAAS), the post-dexamethasone saline infusion test (D-SIT) and the overnight dexamethasone, captopril, valsartan test (DCVT) using pharmaceutical RAAS blockade, a higher prevalenc...

Adrenocortical carcinoma (ACC) is a rare, aggressive tumor with poor prognosis, affecting 0.5–2 cases/106population/year.Objective: To analyse retrospectively characteristics, management and outcome of ACC patients, followed in our center between 2010–2018.Material and methods: The medical records related to diagnosis, treatment and follow-up of nine patients of 59.2±13.8 years with histological diagnosis ...

Introduction: Primary aldosteronism (PA) is the most common cause of endocrine hypertension. Its prevalence varies from 5-15%, which depends mainly on the cut-offs of the diagnostic tests.Aim: To estimate the prevalence of PA in patients with different stages of hypertension based on a dynamic overnight diagnostic test.Methods: One hundred ninety nine hypertensive patients were divided in 3 groups according to the stage of hyperten...

Introduction: Primary aldosteronism (PA) treatment is either pharmacological with aldosterone receptor antagonists (MRAs) or surgical with the resection of the responsible adenoma. The efficacy of MRAs treatment is based on the normalization of blood pressure (BP) in relation to potassium levels. However, it remains unclear whether the stimulation of renin levels during treatment could serve as an additional marker of adequate MR blockade.Aim: To investi...